Intellia Reports Positive Pivotal Trial Results for CRISPR-Based Treatment of Rare Swelling Disease

Intellia Therapeutics announced on Monday, April 27, 2026, that its CRISPR-based treatment lonvo-z dramatically reduced swelling attacks by 87% relative to placebo in a Phase 3 trial enrolling 80 patients with hereditary angioedema, a rare genetic disorder. Just over 60% of patients receiving lonvo-z were entirely attack-free compared to 11% on placebo. The company has initiated a rolling FDA submission for lonvo-z, which would become the second approved CRISPR-based medicine after Vertex's Casgevy and the first in vivo CRISPR treatment that edits DNA directly inside patients' bodies rather than in extracted cells.

Pivotal trial results for lonvo-z CRISPR treatment

• ▪Intellia Therapeutics has initiated a rolling submission with the FDA for lonvo-z.
• ▪The lonvo-z Phase 3 trial enrolled 80 patients with hereditary angioedema.
• ▪Intellia Therapeutics announced on Monday, April 27, 2026, that a single dose of lonvo-z dramatically reduced swelling attacks in patients with a rare genetic disorder in a Phase 3 trial.

Significance as first in vivo gene editing therapy

• ▪Lonvo-z would be the first in vivo CRISPR treatment, meaning it edits patients' DNA directly in the body.
• ▪Lonvo-z would be the second approved CRISPR-based medicine, after Vertex Pharmaceutical's sickle cell treatment Casgevy.

Clinical outcomes in hereditary angioedema patients

• ▪Hereditary angioedema patients who received lonvo-z saw their attack rates drop 87% relative to placebo in the Phase 3 trial.
• ▪Just over 60% of hereditary angioedema patients who received lonvo-z were entirely attack-free over the trial period.

Perspective of Intellia Therapeutics

• ▪The lonvo-z Phase 3 results advance CRISPR gene editing toward regulatory approval for hereditary angioedema.
• ▪Lonvo-z represents a potential one-and-done treatment approach for hereditary angioedema patients.

Perspective of CRISPR field researchers and developers

• ▪Lonvo-z's positive Phase 3 results validate the feasibility of editing patients' DNA directly inside the body.
• ▪In vivo CRISPR treatments like lonvo-z represent a distinct advancement from ex vivo approaches like Casgevy.

1 source